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289Abstracts
SION: The results of this employee survey demonstrate that
beyond migraine severity and medication therapy, there are
potentially modiﬁable employee and provider factors, which sig-
niﬁcantly reduce lost productivity associated with migraines.
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OBJECTIVES: Determine prevalence of employees (via self-
report) experiencing migraine (MID) and non-migraine (NMIG)
headaches; and extent of reduced productivity (absenteeism and
presenteeism) in MIG and NMIG groups. METHODS: A total
of 712 Health Risk Assessments were distributed to health care
workers in a large, multispecialty medical group in Southern Cal-
ifornia; 455 returned (64% response rate). Respondents were
87% female; mean age of 45. Responders classiﬁed into no
headache, migraine (deﬁned by severity and frequency of symp-
toms using IHS criteria), and non-migraine. Headache sufferers
were asked about absenteeism (full and partial days missed due
to headache) and presenteeism (days worked with headache and
self-reported productivity with headache) over the most recent 4
week period. RESULTS: Twenty-ﬁve percent reported having no
headaches in past 6 months, 35% had non-migraine headaches,
and 40% had migraines. Combining absenteeism and presen-
teeism, 68.3% MIG and 44.7% NMIG sufferers reported pro-
ductivity loss due to headaches in the prior 4 week period. MIG
sufferers reported a mean of 9.72 hours of lost productivity, of
which 8.13 hours were due to presenteeism. NMIG employees
reported a mean of 3.94 hours of lost productivity, of which 3.37
were due to presenteeism. On annualized basis, employees with
migraines lost total of 15.85 days: 13.21 days due to presen-
teeism, 1.78 days due to full missed work days and 0.86 days
due to partial missed days. The annual cost to the medical group
for lost productivity for headache employees is $887,976 ($1247
per employee): $645,161 for MIG sufferers and $229,815 
for NMIG employees. CONCLUSIONS: The results of this
employee survey demonstrate that migraine headaches are both
a prevalent and expensive condition for an employer. The mag-
nitude of the cost is surprisingly large in a health care organiza-
tion with employees who would be assumed to be fairly
sophisticated and have ready access to physicians for diagnosis
and treatment.
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Both ergotamine and tritpans are currently used in the treatment
of acute migraine. Ergotamine is a traditional therapy with lower
drug acquisition cost and less headache recurrence. It has been
showed that tritpans are more efﬁcacious than ergotamine. But
their high acquisition costs and the short duration of action
remain as their major disadvantages. OBJECTIVE: The purpose
of this study is to provide a comparison of cost-effectiveness of
rizatriptan and sumatritpan with Cafergot in the treatment of
acute migraine attack. METHODS: Three separate models were
developed based on a decision tree (Model 1: rizatriptan 
vs. Cafergot; Model 2: sumatritpan vs. Cafergot; Model 3: 
rizatritpan vs. sumatritpan). Time horizon was one year. Cost-
effectiveness analysis was conducted from the societal perspec-
tive using data from the literature. All costs were converted to
year 2003 dollars. The CE ratio was expressed in incremental
cost/incremental QALYs. RESULTS: Base case evaluation
showed that both rizatriptan and sumatriptan dominated 
Cafergot (provide the cost differences and QALY differences for
the different Meds). Sensitivity analysis showed that the CE
ratios were sensitive to moderate changes in effectiveness of trip-
tans. The study further showed that rizatritpan is more cost-
effective than sumatriptan, as evidenced by the negative CE ratio.
Cost-effective ratios are not sensitive to changes of key variables,
which include efﬁcacy, utility, drug costs, hospitalization cost
and patient preference over alternative therapies. CONCLU-
SION: Rizatriptan and sumatritpan are both more cost-effective
than Cafergot in the treatment of acute migraine attack. Riza-
tritpan also dominated sumatritpan. Additional quality of life
studies are needed to conﬁrm the beneﬁt from using triptans in
management of migraine.
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OBJECTIVES: The objectives of this study were to compare the
clinical efﬁcacy and cost-effectiveness of eletriptan 40mg vs.
sumatriptan 100mg for the acute treatment of migraine attack.
METHODS: Data were extracted and pooled from three ran-
domized head-to-head clinical trials comparing the efﬁcacy of
eletriptan 40mg and sumatriptan 100mg. Three composite mea-
sures of treatment success were used based on sustained response
(no recurrence of moderate to severe headache or use of rescue
medication from the stated time period to 24 hours post-dose):
1-hour sustained response, with improvement of headache pain
from moderate to severe at baseline to mild or absent within 1
hour; 2-hour sustained response, with improvement to absent or
mild pain within 2 hours post-dose; and 2-hour sustained pain-
free, with improvement to pain-free within 2 hours. The cost per
successfully treated patient (CPSTP) was calculated for each
outcome based on the wholesale acquisition cost (WAC) for 
each medication (AnalySource®, September 2003). The 95%
conﬁdence interval (CI) was calculated using bootstrapping 
technique. RESULTS: Eletriptan 40mg was superior to suma-
triptan 100mg across each of the three outcomes: 1-hour sus-
tained, 20% vs. 15% (P < 0.01); 2-hour sustained, 41% vs. 34%
(P < 0.001); and 2-hour sustained pain-free, 22% vs. 15% 
(P < 0.0001). The CPSTP was lower for eletriptan than suma-
triptan for all three measures: 1-hour sustained response, $81 
vs. $129; 2-hour sustained, $40 vs. $57; 2-hour sustained pain-
free, $74 vs. $133. CONCLUSIONS: Eletriptan 40mg had 
consistently greater positive clinical impact than sumatrip-
tan 100mg in the acute treatment of migraine. The greater 
efﬁcacy and lower recurrence rate also translated into better 
cost-effectiveness.
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